Two biotechs target dry eye disease after Novartis’ Xiidra problemsThe pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, Share XTwo biotechs target dry eye disease after Novartis’ Xiidra problemshttps://pharmaphorum.com/news/two-biotechs/
